PARP
FDA rejects olaparib
June 27, 2014Sales and Marketing AstraZeneca, Cancer, FDA, PARP, adp, olaparib
AstraZeneca has been dealt a blow by a key advisory committee to the US Food and Drug Administration, which has …
Sanofi’s BSI-201 tipped for success in triple negative breast cancer
February 28, 2010Sales and Marketing Cancer, PARP, Sanofi, breast cancer
Sanofi-Aventis’s BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in 2018, according to …
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
